AU2001274786A1 - Method for the treatment of overactive bladder - Google Patents

Method for the treatment of overactive bladder

Info

Publication number
AU2001274786A1
AU2001274786A1 AU2001274786A AU7478601A AU2001274786A1 AU 2001274786 A1 AU2001274786 A1 AU 2001274786A1 AU 2001274786 A AU2001274786 A AU 2001274786A AU 7478601 A AU7478601 A AU 7478601A AU 2001274786 A1 AU2001274786 A1 AU 2001274786A1
Authority
AU
Australia
Prior art keywords
treatment
overactive bladder
compound
methods
oxoperhydropyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001274786A
Inventor
David Aharony
Peter Bernstein
Russell A. Bialecki
William Rumsey
Keith Russell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2001274786A1 publication Critical patent/AU2001274786A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Treatment or prevention of overactive bladder or urinary incontinence in mammals, particularly humans, using (S)-N-[2-(3,4-dichlorophenyl)-4-[4-(2-oxoperhydropyrimidin-1-yl)piperidino]butyl]-N-methylbenzamide, pharmaceutically-advantageous salts of the compound, methods of use of the compound, either alone or in combination with other pharmacological agents, and pharmaceutical compositions useful in practising the methods of the invention.
AU2001274786A 2000-06-22 2001-06-20 Method for the treatment of overactive bladder Abandoned AU2001274786A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0015246 2000-06-22
GBGB0015246.2A GB0015246D0 (en) 2000-06-22 2000-06-22 Method for the treatment of urinary incontinence
PCT/SE2001/001420 WO2001097811A1 (en) 2000-06-22 2001-06-20 Method for the treatment of overactive bladder

Publications (1)

Publication Number Publication Date
AU2001274786A1 true AU2001274786A1 (en) 2002-01-02

Family

ID=9894138

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001274786A Abandoned AU2001274786A1 (en) 2000-06-22 2001-06-20 Method for the treatment of overactive bladder

Country Status (9)

Country Link
US (1) US20030139433A1 (en)
EP (1) EP1307202B1 (en)
JP (1) JP2003535901A (en)
AT (1) ATE326223T1 (en)
AU (1) AU2001274786A1 (en)
DE (1) DE60119742T2 (en)
ES (1) ES2262654T3 (en)
GB (1) GB0015246D0 (en)
WO (1) WO2001097811A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002036144A1 (en) * 2000-10-30 2002-05-10 University Of Zurich Gnrh analogues for treatment of urinary incontinence
SE0103795D0 (en) 2001-11-02 2001-11-02 Astrazeneca Ab Compounds and method for the treatment of overactive bladder
SE0103668D0 (en) * 2001-11-02 2001-11-02 Astrazeneca Ab Method for the treatment of overactive leaves
US20040248989A1 (en) 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
CN1874766A (en) * 2003-10-27 2006-12-06 诺瓦提斯公司 Use of neurokinin antagonists in the treatment of urinary incontinence
WO2006121389A1 (en) * 2005-05-10 2006-11-16 Astrazeneca Ab Use of a neurokinin-2 receptor antagonist for treating or preventing detrusor overactivity
CN117695286A (en) * 2017-06-06 2024-03-15 住友制药(苏州)有限公司 Treatment of overactive bladder with velbegron
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9317104D0 (en) * 1993-08-17 1993-09-29 Zeneca Ltd Therapeutic heterocycles
GB9322643D0 (en) * 1993-11-03 1993-12-22 Zeneca Ltd Lactam derivatives
US6008223A (en) * 1994-10-27 1999-12-28 Zeneca Limited Therapeutic compounds
GB9505084D0 (en) * 1995-03-14 1995-05-03 Pfizer Ltd Benzamide derivative
BR9912013A (en) * 1998-07-10 2001-04-10 Astrazeneca Ab Compound, pharmaceutical composition, method of treating a disease condition, and process for preparing a compound
GB9922519D0 (en) * 1998-10-07 1999-11-24 Zeneca Ltd Compounds
GB9924141D0 (en) * 1998-10-30 1999-12-15 Zeneca Ltd Treatment of gastric asthma
GB9826941D0 (en) * 1998-12-09 1999-02-03 Zeneca Pharmaceuticals Compounds

Also Published As

Publication number Publication date
DE60119742D1 (en) 2006-06-22
WO2001097811A1 (en) 2001-12-27
JP2003535901A (en) 2003-12-02
ES2262654T3 (en) 2006-12-01
ATE326223T1 (en) 2006-06-15
US20030139433A1 (en) 2003-07-24
EP1307202B1 (en) 2006-05-17
GB0015246D0 (en) 2000-08-16
DE60119742T2 (en) 2007-05-31
EP1307202A1 (en) 2003-05-07

Similar Documents

Publication Publication Date Title
WO2001066564A3 (en) Gamma-secretase inhibitors
SE9900100D0 (en) New compounds
EP1764092A3 (en) Selecting compounds for treatment of Alzheimer's disease
BG105783A (en) Triazole compounds with dopamine-d3-receptor affinity
WO2001079460A3 (en) Polypeptides having haloperoxidase activity
GB9917406D0 (en) Compounds
MXPA04000586A (en) Combination of an aldosterone receptor antagonist and an hmg coa reductase inhibitor.
WO2001032652A3 (en) N-substituted carbamoyloxyalkyl-azolium derivatives
ATE224884T1 (en) MUSCARINE ANTAGONISTS
EP1920771A3 (en) Methods of treating hyperlipidemia
AU2001274786A1 (en) Method for the treatment of overactive bladder
MXPA05007771A (en) Methods for treating joint pain or improving sleep using an estrogen agonist/antagonist.
AU4651700A (en) Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases
WO2001056555A3 (en) Use of cox-2 inhibitors for the treatment of constipation
AU2001290480A1 (en) Cyclized benzamide neurokinin antagonists for use in therapy
MXPA02000330A (en) Neurotrophic pyrrolidines and piperidines, and related compositions and methods.
BR0213832A (en) Compound, method for treating or preventing overactive bladder or urinary incontinence in an individual, pharmaceutical composition, and use of -n- [2- (3,4-dichlorophenyl) -4- [4- (2-oxo -piperidin-1-yl) piperidino] butyl] -n-methyl-2-fluorobenzamide or a pharmaceutically acceptable salt thereof
WO2001089498A3 (en) USE OF (+)-α -(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL OR ITS PRODRUG IN THE TREATMENT OF SYMPTOMS OF DEMENTIA AND DOPAMINE INDUCED PSYCHOSIS
WO2002091990A3 (en) Prevention of addiction in pain management
WO2002024727A3 (en) New inhibitors of iapp fibril formation and uses thereof
WO2001046178A3 (en) Substituierte bisindolymaleimide
MXPA04004071A (en) Method for the treatment of overactive bladder.
WO2005113526A3 (en) Metabolites of 4-(3,4-dichloro-phenyl)-2-[2-(4-methyl-piperazin-1-yl)-benzylidene]-thiomorpholin-3-one
WO2002044159A3 (en) 1-(2-m-methanesulfonamidophenylethyl)-4-(m-trifluoromethylphenyl)piperazine and pharmaceutically acceptable salts and solvates thereof and their use in the treatment of incontinence
WO2001041769A3 (en) Combination of cyamemazine and an atypical neuroleptic